论文部分内容阅读
目的观察丹红注射液联合依达拉奉注射液治疗急性脑梗死的临床疗效。方法 180例急性脑梗死患者随机分为研究组与对照组,每组90例,对照组在常规治疗基础上给予依达拉奉注射液治疗,研究组在对照组基础上加用丹红注射液治疗,两组治疗周期均为14 d,治疗结束后评定疗效。结果治疗结束后,研究组临床总有效率为92.22%,显著优于对照组的72.22%(P<0.05);研究组患者神经功能缺损评分显著低于对照组(P<0.05)。结论丹红注射液联合依达拉奉注射液治疗脑梗死的临床疗效确切,值得在临床进行推广。
Objective To observe the clinical efficacy of Danhong injection combined with edaravone injection in the treatment of acute cerebral infarction. Methods 180 patients with acute cerebral infarction were randomly divided into study group and control group, 90 cases in each group. The control group was treated with edaravone on the basis of conventional treatment. The study group was given Danhong injection on the basis of the control group Treatment, two treatment cycles were 14 d, after curative effect assessment. Results After the treatment, the total effective rate of the study group was 92.22%, which was significantly better than that of the control group (72.22%, P <0.05). The neurological deficit score of the study group was significantly lower than that of the control group (P <0.05). Conclusion Danhong injection combined with edaravone injection in the treatment of cerebral infarction clinical efficacy is exact, it is worth in the clinical promotion.